- Conditions
- Intraoperative Bleeding, Liver Diseases, Gallbladder Diseases, Hemorrhage, Surgical
- Interventions
- GATT-Patch, SURGICEL® Original
- Device
- Lead sponsor
- GATT Technologies BV
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Los Angeles, California • St Louis, Missouri • Pennington, New Jersey + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 719
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Disorders of the Pancreas and Biliary Tree
- Interventions
- ERCP as per medical indication
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Gall Bladder Cancer, Cholangiocarcinoma
- Interventions
- IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody
- Drug
- Lead sponsor
- Iksuda Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Combination antiviral therapy, Placebo
- Drug
- Lead sponsor
- University of Alberta
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • St Louis, Missouri
- Conditions
- Biliary Tract Cancer (BTC)
- Interventions
- D07001-Softgel Capsules, Placebo, Capecitabine
- Drug · Combination Product
- Lead sponsor
- InnoPharmax Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Miami Beach, Florida • Cleveland, Ohio + 1 more
- Conditions
- Pregnancy Complications, Acute Appendicitis, Acute Cholecystitis, Biliary Pancreatitis, Bowel Obstruction, Acute Diverticulitis
- Interventions
- non-obstetric acute general surgical disease
- Procedure
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Choledocholithiasis, Bile Duct Diseases, Bile Duct Carcinoma
- Interventions
- "Air" contrast cholangiography using carbon dioxide gas
- Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Primary Biliary Cholangitis
- Interventions
- CNP-104, Placebo
- Drug
- Lead sponsor
- COUR Pharmaceutical Development Company, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 19
- States / cities
- Coronado, California • Lancaster, California • Sacramento, California + 16 more
- Conditions
- Primary Sclerosing Cholangitis, Liver Transplant, Complications, PSC, Biliary Strictures
- Interventions
- Fenofibrate (drug), Blood draw for the laboratory assessment, MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)
- Drug · Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Total Parenteral Nutrition-induced Cholestasis
- Interventions
- Omegaven, Omegaven
- Dietary Supplement · Drug
- Lead sponsor
- Pediatrix
- Other
- Eligibility
- 14 Days to 2 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Biliary Tract Cancer
- Interventions
- Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, Rilvegostomig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 48
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Fullerton, California + 38 more
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Moexipril
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Cholestasis, Liver Disease
- Interventions
- Omegaven IV
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 1 Day to 5 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Staten Island, New York
- Conditions
- KRAS G12D Mutation, Advanced Solid Cancer
- Interventions
- ARV-806
- Drug
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 9 more
- Conditions
- Biliary Atresia
- Interventions
- Maralixibat, Placebo
- Drug · Other
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Days to 111 Days
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • New York, New York + 3 more
- Conditions
- Cholecystitis
- Interventions
- Injection of indocyanine green (ICG), Near Infrared Cholangiography Fluorescence (NIRF-C)
- Drug · Device
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Recurrent Colon Cancer, Liver Metastases, Stage IV Rectal Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer
- Interventions
- floxuridine, leucovorin calcium, melphalan
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- Not listed
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma
- Interventions
- XmAb20717
- Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 12 more
- Conditions
- Cancer of the Bile Duct, Gallbladder Cancer
- Interventions
- GM-CT-01, 5-Fluorouracil
- Drug
- Lead sponsor
- Galectin Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • Cincinnati, Ohio
- Conditions
- Biliary Dyskinesia, Gallstones, Cholecystitis, Cholelithiasis
- Interventions
- Single-Incision Laparoscopic Surgery cholecystectomy, Traditional Laparoscopic Cholecystectomy (TLC)
- Procedure
- Lead sponsor
- Saint Luke's Health System
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Biliary Tract Cancer
- Interventions
- Rucaparib, Nivolumab
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • Nashville, Tennessee
- Conditions
- Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Biliary Tract Carcinoma
- Interventions
- DISP-10
- Biological
- Lead sponsor
- Dispatch Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2046
- U.S. locations
- 7
- States / cities
- Duarte, California • Newport Beach, California • Tampa, Florida + 4 more
- Conditions
- Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
- Interventions
- Trastuzumab, Pertuzumab, Erlotinib, Vemurafenib, Cobimetinib, Vismodegib, Alectinib, Atezolizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 60
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Springdale, Arkansas + 47 more
- Conditions
- Biliary Atresia
- Interventions
- Odevixibat, Placebo
- Drug
- Lead sponsor
- Albireo, an Ipsen Company
- Industry
- Eligibility
- Up to 111 Days
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 30
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 25 more